References
- Alonen A, Finel M, Kostiainen R. (2008). The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan. Biochem Pharmacol 76:763–72. https://doi.org/10.1016/j.bcp.2008.07.006
- Aquilante CL, Kosmiski LA, Bourne DWA, et al. (2013). Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Br J Clin Pharmacol 75:217–26. https://doi.org/10.1111/j.1365-2125.2012.04343.x
- Bae J-W, Jang C-G, Lee S-Y. (2011). Effects of clopidogrel on the pharmacokinetics of sibutramine and its active metabolites. J Clin Pharmacol 51:1704–11. https://doi.org/10.1177/0091270010388651
- Baer BR, DeLisle RK, Allen A. (2009). Benzylic oxidation of gemfibrozil-1-O-beta-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition. Chem Res Toxicol 22:1298–309. https://doi.org/10.1021/tx900105n
- Bosilkovska M, Samer CF, Déglon J, et al. (2014). Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots. Clin Pharmacol Ther 96:349–59. https://doi.org/10.1038/clpt.2014.83
- Böttiger Y, Tybring G, Götharson E, Bertilsson L. (1997). Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 62:384–91. https://doi.org/10.1016/S0009-9236(97)90116-8
- Buchheit D, Dragan C-A, Schmitt EI, Bureik M. (2011). Production of ibuprofen acyl glucosides by human UGT2B7. Drug Metab Dispos Biol Fate Chem 39:2174–81. https://doi.org/10.1124/dmd.111.041640
- Crespi CL, Penman BW. (1997). Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug–drug interactions. Adv Pharmacol San Diego Calif 43:171–88
- Dong D, Wu B, Chow D, Hu M. (2012). Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling. Drug Metab Rev 44:192–208
- EMA. (2012). Guideline on the investigation of drug interactions. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf
- FDA. (2012). Guidance for industry: drug interaction studies – study design, data analysis, implications for dosing, and labeling recommendations
- FDA. (2017). Guidance for industry. In vitro metabolism and transporter mediated drug-drug interaction studies. Available from: https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm581965.pdf
- Fowler S, Zhang H. (2008). In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. Aaps J 10:410–24. https://doi.org/10.1208/s12248-008-9042-7
- Gibbons JA, de Vries M, Krauwinkel W, et al. (2015). Pharmacokinetic drug interaction studies with Enzalutamide. Clin Pharmacokinet 54:1057–69. https://doi.org/10.1007/s40262-015-0283-1
- Godoy P, Hewitt NJ, Albrecht U, et al. (2013). Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 87:1315–530. https://doi.org/10.1007/s00204-013-1078-5
- Guest EJ, Rowland-Yeo K, Rostami-Hodjegan A, et al. (2011). Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models. Br J Clin Pharmacol 71:72–87
- Härtter S, Grözinger M, Weigmann H, et al. (2000). Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin Pharmacol Ther 67:1–6. https://doi.org/10.1067/mcp.2000.104071
- Hemeryck A, De Vriendt CA, Belpaire FM. (2001). Metoprolol-paroxetine interaction in human liver microsomes: stereoselective aspects and prediction of the in vivo interaction. Drug Metab Dispos Biol Fate Chem 29:656–63
- Hesse LM, Venkatakrishnan K, Court MH, et al. (2000). CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos Biol Fate Chem 28:1176–83
- Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. (2011). Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans. Clin Pharmacol Ther 89:579–86. https://doi.org/10.1038/clpt.2010.358
- Huang S-M, Rowland M. (2012). The role of physiologically based pharmacokinetic modeling in regulatory review. Clin Pharmacol Ther 91:542–9. https://doi.org/10.1038/clpt.2011.320
- Hutzler JM, Ring BJ, Anderson SR. (2015). Low-turnover drug molecules: a current challenge for drug metabolism scientists. Drug Metab Dispos 43:1917–28
- Hynninen V-V, Olkkola KT, Leino K, et al. (2006). Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen. Antimicrob Agents Chemother 50:1967–72. https://doi.org/10.1128/AAC.01483-05
- Iga K. (2015). Simulation of metabolic drug-drug interactions perpetrated by Fluvoxamine using Hybridized two-compartment Hepatic Drug-Pool-based tube modeling and estimation of in vivo inhibition constants. J Pharm Sci 104:3565–77. https://doi.org/10.1002/jps.24549
- Kang BC, Yang CQ, Cho HK, et al. (2002). Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharm Drug Dispos 23:77–81
- Kazierad DJ, Martin DE, Blum RA, et al. (1997). Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther 62:417–25. https://doi.org/10.1016/S0009-9236(97)90120-X
- Moody GC, Griffin SJ, Mather AN, et al. (1999). Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica Fate Foreign Compd Biol Syst 29:53–75. https://doi.org/10.1080/004982599238812
- Mori K, Hashimoto H, Takatsu H, et al. (2009). Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development. Xenobiotica Fate Foreign Compd Biol Syst 39:415–22. https://doi.org/10.1080/00498250902822204
- Niemi M, Backman JT, Neuvonen M, et al. (2001). Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 69:194–200. https://doi.org/10.1067/mcp.2001.114229
- Niemi M, Tornio A, Pasanen MK, et al. (2006). Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. Eur J Clin Pharmacol 62:463–72. https://doi.org/10.1007/s00228-006-0133-z
- Njuguna NM, Umehara K-I, Huth F, et al. (2016). Improvement of the chemical inhibition phenotyping assay by cross-reactivity correction. Drug Metab Pers Ther 31:221–8. https://doi.org/10.1515/dmpt-2016-0028
- Obach RS, Baxter JG, Liston TE, et al. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46–58
- Obach RS, Cox LM, Tremaine LM. (2005). Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos Biol Fate Chem 33:262–70. https://doi.org/10.1124/dmd.104.002428
- Ogilvie BW, Torres R, Dressman MA, et al. (2015). Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. J Clin Pharmacol 55:1004–11. https://doi.org/10.1002/jcph.507
- Ogilvie BW, Usuki E, Yerino P, Parkinson A. 2008. In Vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the tabolism of drugs (reaction phenotyping) with emphasis on cytochrome P450. In: Rodrigues AD, ed. Drug–drug interactions, drugs and the pharmaceutical sciences. New York: Informa Healthcare, 231–358
- Olkkola KT, Backman JT, Neuvonen PJ. (1994). Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481–5
- Parmentier Y, Bossant M-J, Bertrand M, Walther B. (2007). In vitro studies of drug metabolism. In: Reedijk J, ed. Chemistry, Molecular sciences and chemical engineering, from comprehensive medicinal chemistry II. Waltham: Elsevier, Volume 5, 231–57
- Parmentier Y, Pothier C, Delmas A, et al. (2017). Direct and quantitative evaluation of the human CYP3A4 contribution (fm) to drug clearance using the in vitro SILENSOMES model. Xenobiotica Fate Foreign Compd Biol Syst 47:562–75. https://doi.org/10.1080/00498254.2016.1208854
- Perloff ES, Mason AK, Dehal SS, et al. (2009). Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design. Xenobiotica Fate Foreign Compd Biol Syst 39:99–112. https://doi.org/10.1080/00498250802638155
- Rendic S, Guengerich FP. (2015). Survey of human oxidoreductases and cytochrome P450 enzymes involved in the metabolism of xenobiotic and natural chemicals. Chem Res Toxicol 28:38–42
- Rowland M, Matin SB. (1973). Kinetics of drug-drug interactions. J Pharmacokinet Biopharm 1:553–67
- Richter T, Schwab M, Eichelbaum M, Zanger UM. (2005). Inhibition of human CYP2B6 by N,N',N''-triethylenethiophosphoramide is irreversible and mechanism-based. Biochem Pharmacol 69:517–24. https://doi.org/10.1016/j.bcp.2004.10.008
- Roy P, Yu LJ, Crespi CL, Waxman DJ. (1999). Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos Biol Fate Chem 27:655–66
- Ruwe FJL, Smulders RA, Kleijn HJ, et al. (2001). Mirtazapine and paroxetine: a drug-drug interaction study in healthy subjects. Hum Psychopharmacol 16:449–59. https://doi.org/10.1002/hup.318
- Sai Y, Dai R, Yang TJ, et al. (2000). Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica Fate Foreign Compd Biol Syst 30:327–43. https://doi.org/10.1080/004982500237541
- Sheiner LB, Beal SL. (1981). Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503–12
- Stout SM, Nielsen J, Bleske BE, et al. (2010). The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics. J Cardiovasc Pharmacol Ther 15:373–9
- Troost J, Tatami S, Tsuda Y, et al. (2011). Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. Br J Clin Pharmacol 72:247–56. https://doi.org/10.1111/j.1365-2125.2011.03988.x
- Uttamsingh V, Gallegos R, Liu JF, et al. (2015). Altering metabolic profiles of drugs by precision deuteration: reducing mechanism-based inhibition of CYP2D6 by paroxetine. J Pharmacol Exp Ther 354:43–54. https://doi.org/10.1124/jpet.115.223768
- Varhe A, Olkkola KT, Neuvonen PJ. (1996). Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. Br J Clin Pharmacol 42:465–70
- Venkatakrishnan K, Moltke LLV, Greenblatt DJ. (1998). Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. J Pharm Sci 87:1502–7. https://doi.org/10.1021/js980255z
- Venkatakrishnan K, von Moltke LL, Harmatz JS, et al. (2000). Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab. Dispos 28:1493–504
- Wang RW, Newton DJ, Liu N, et al. (2000). Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos Biol Fate Chem 28:360–6
- Wienkers L, Stevens J. 2003. Cytochrome P450 reaction phenotyping. In: Lee J, Obach RS, Fisher MB, eds. Drug metabolizing enzymes: cytochrome P450 and other enzymes in drug discovery and development. New York: FontisMedia SA, 255–310
- Winnenburg R, Bodenreider O. (2014). A framework for assessing the consistency of drug classes across sources. J Biomed Semantics 5:30. https://doi.org/10.1186/2041-1480-5-30
- Yamazaki H, Inoue K, Turvy CG, et al. (1997). Effects of freezing, thawing, and storage of human liver samples on the microsomal contents and activities of cytochrome P450 enzymes. Drug Metab Dispos Biol Fate Chem 25:168–74
- Yang X, Atkinson K, Di L. (2016). Novel cytochrome P450 reaction phenotyping for low-clearance compounds using the hepatocyte relay method. Drug Metab Dispos 44:460–5
- Yasui-Furukori N, Takahata T, Nakagami T, et al. (2004). Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol 57:487–94. https://doi.org/10.1111/j.1365-2125.2003.02047.x
- Yoshizato T, Kotegawa T, Imai H, et al. (2012). Itraconazole and domperidone: a placebo-controlled drug interaction study. Eur J Clin Pharmacol 68:1287–94. https://doi.org/10.1007/s00228-012-1258-x
- Zhang H, Davis CD, Sinz MW, Rodrigues AD. (2007). Cytochrome P450 reaction-phenotyping: an industrial perspective. Expert Opin Drug Metab Toxicol 3:667–87. https://doi.org/10.1517/17425255.3.5.667
- Zhou HH, Anthony LB, Roden DM, Wood AJ. (1990). Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. Clin Pharmacol Ther 47:686–93
- Zhou S, Chan E, Lim LY, et al. (2004). Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 5:415–42